ArticlePeerJ2026
Mannose-engineered nanoparticles for site-specific delivery of fluconazole to treat cutaneous leishmaniasis.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous leishmaniasis (CL) is a skin disease that affects people living in arid and semi-arid regions. The main limitation in current management is that treatment primarily targets the cutaneous lesions, while immune-mediated effects is often not addressed. In addition, there is a need for new treatment with minimized side effects. Fluconazole (FCZ) has been used for treating CL before. Methods: In the present study, FCZ was entrapped in a chitosan (CS) nanopolymer and conjugated with mannose (MNS) to target amastigotes inside macrophages in CL-infected Balb/c male mice. Parasites were detected using Enzyme-Linked Immunosorbent Assay (ELISA) and Polymerase chain reaction (PCR). Results: The resulting FCZ CS MNS NPs nanoparticles exhibited small size (71.96 ± 11.4 nm) good stability (31.2 ± 0.173 nm), release over an extended period, and long-term bioavailability. The FCZ CS MNS nanoparticle-treated mice showed negative PCR results and low IgG levels compared to the positive control (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.